Expression Analysis Announces 2013 Grant Program
News Apr 08, 2013
Expression Analysis (EA), a Quintiles company today announced a grant program that provides scientists with leading-edge products and services to advance genomics research. In the fifth year of EA’s grant program, EA and Illumina will award two grant winners fully-funded exome and RNA sequencing services along with array-based methylation analysis as part of the companies’ integrated biology grant.
“This grant program illustrates our commitment to advancing new applications in genomics research,” said Steve McPhail, President of EA. “We are encouraging researchers to explore the power of an integrated biological approach in their genetic research studies.”
“We are very excited to enable this comprehensive approach using the latest advances in genomic studies enhanced with gene expression and regulation,” said Tristan Orpin, Senior Vice President and Chief Commercial Officer of Illumina. “We look forward to another successful partnership with EA in co-sponsoring these grants.”
Integrated biology is a scientific approach that has considerable advantages over other approaches within biology and biomedical research—including interpreting interactions in genetic research studies through a comprehensive, systems view rather than a single scientific lens that can exclude significant biological factors.
The integrated biology grant includes:
• Whole Genome DNA Methylation, which plays a critical role in the regulation of gene expression and is known to be an essential mechanism for guiding normal cellular development and maintaining tissue identities;
• RNA Sequencing, which enables a more comprehensive and quantitative view of the entire transcriptome, providing accurate analysis of gene expression. This also enables identification of novel transcripts, novel isoforms, alternative splice sites, allele-specific expression, cSNPs, and rare transcripts all in a single experiment; and
• Exome Sequencing, which integrates protein coding regions of the human genome through enrichment strategies that target all exons, UTRs and other functionally annotated regions of interest.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019